Wnt-5a: Complete Research Profile — ROR1/ROR2 Non-Canonical Receptor Biology, Wnt/PCP and Wnt/Ca²⁺ Signaling Cascades, Cancer Invasion and EMT Mechanisms, Inflammatory Macrophage Polarization, and Research Applications (2026)

# Wnt-5a: Complete Research Profile — ROR1/ROR2 Non-Canonical Receptor Biology, Wnt/PCP and Wnt/Ca²⁺ Signaling Cascades, Cancer Invasion and EMT Mechanisms, Inflammatory Macrophage Polarization, and Research Applications (2026)

Introduction

Wnt-5a is a prototypical non-canonical Wnt ligand — one of 19 mammalian Wnt glycoproteins — that activates planar cell polarity (PCP) and Wnt/Ca²⁺ pathways while actively antagonizing canonical Wnt/β-catenin signaling in most cellular contexts. First identified through its expression in the developing mouse embryo, Wnt-5a has since emerged as a master regulator of cell polarity, directional migration, and tissue morphogenesis, with critical roles in limb elongation, neural crest migration, and establishment of left-right body asymmetry.

In cancer biology, Wnt-5a occupies an ambiguous position: it functions as a tumor suppressor in hematopoietic malignancies (where β-catenin activation drives progression) while acting as a pro-invasive, pro-metastatic factor in solid tumors including melanoma, breast, gastric, and colorectal cancers, where it drives epithelial-mesenchymal transition (EMT) and cytoskeletal remodeling via ROR1/ROR2 receptor tyrosine kinase-like receptors. This context-dependence — suppressor vs. promoter — is determined by the relative expression of Frizzled co-receptors vs. ROR1/2, and by the downstream β-catenin vs. PCP pathway balance in a given cell type.

In the immune compartment, Wnt-5a drives inflammatory macrophage polarization (M1-like) via JNK/AP-1 and NF-κB, while simultaneously being produced by Th17 cells to amplify inflammatory responses in autoimmune disease models.

For research investigators working with cell migration assays, EMT models, tumor invasion biology, or immune cell polarization systems, this profile provides the mechanistic depth required to design, interpret, and troubleshoot Wnt-5a-centered experiments.

---

Molecular Structure and Biosynthesis

Wnt-5a Protein Architecture

Human Wnt-5a (UniProt P41221) is a 380-amino acid secreted glycoprotein with:

• •Signal peptide (aa 1–21): ER targeting
• •Mature secreted chain (aa 22–380): 359 aa, predicted MW ~43 kDa; apparent MW on SDS-PAGE ~55–65 kDa (glycosylated)
• •Conserved cysteine framework: 23 conserved cysteines forming 11 disulfide bonds essential for the Wnt-fold; mutations in these cysteines abolish activity
• •N-linked glycosylation: N-linked glycans at N-41 and N-302 required for proper folding and secretion
• •Palmitoylation at S209: single O-linked palmitate on a conserved serine (equivalent to S209 in murine Wnt-3a); palmitoyltransferase Porcupine (PORCN) adds this modification in the ER — essential for Wnt activity and Wntless (WLS)-mediated secretion

The dual lipidation creates the amphipathic character of mature Wnt proteins that drives their association with lipoproteins and exosomes for long-range transport. Without Porcupine-mediated palmitoylation, Wnt-5a is retained intracellularly and fails to bind Frizzled or ROR receptors with high affinity. Porcupine inhibitors (LGK-974, WNT-974, ETC-159) therefore block all Wnt ligand activity including Wnt-5a.

Secretion and Extracellular Trafficking

Palmitoylated Wnt-5a is loaded onto WLS (Wntless/Evi/Sprinter) for Golgi to plasma membrane trafficking. At the cell surface, Wnt-5a is:

1. Shed on lipoprotein particles (Wnt-lipoprotein complexes for long-range signaling)

2. Released on exosomes (exosomal Wnt for short-range paracrine signaling in tumor niches)

3. Retained at the cell surface via HSPG (glypicans GPC3/GPC4, syndecan SDC1/4) binding through the conserved basic patch — driving autocrine/juxtacrine signaling geometry in tumor cells

HSPG binding is mechanistically important: heparanase-mediated HSPG cleavage can liberate surface-retained Wnt-5a, and heparin competition assays (soluble heparin 10–50 µg/mL) reduce effective Wnt-5a concentration at ROR receptors in vitro.

---

Receptor Systems: ROR1 and ROR2

ROR Receptor Family

ROR1 and ROR2 are orphan receptor tyrosine kinase-like proteins defined by their extracellular cysteine-rich domain (CRD) homologous to Frizzled CRDs — the Wnt-binding domain. Key features:

ROR1 kinase domain is catalytically impaired (lacks key catalytic residues); it functions predominantly as a scaffold/co-receptor. ROR2 has a functional kinase domain with Y641 as the primary activation loop phosphorylation site.

Wnt-5a/ROR2 Signaling Mechanism

The primary Wnt-5a effector pathway in migration and invasion proceeds through ROR2:

1. Wnt-5a binds ROR2 CRD (Kd ~10–50 nM) and Frizzled co-receptor simultaneously

2. ROR2 undergoes Y641 transphosphorylation (possibly by Src or DAAM1-associated kinases)

3. Dvl (Dishevelled) is recruited to the ROR2 cytoplasmic tail via its DEP domain

4. Dvl → DAAM1 (formin) activation → actin polymerization → lamellipodia/filopodia

5. Dvl → Rac1/CDC42/RhoA GTPase exchange factor activation → cytoskeletal remodeling

6. ROR2 → Casein kinase 1ε (CK1ε) → β-catenin phosphorylation (S45) — paradoxically promoting β-catenin degradation (non-canonical route antagonizes canonical Wnt)

Wnt-5a/ROR1 in Cancer

ROR1 is overexpressed in chronic lymphocytic leukemia (CLL), mantle cell lymphoma, acute lymphoblastic leukemia (ALL), and many solid tumor types. In CLL, Wnt-5a/ROR1 signaling:

• •Activates PI3K-AKT-mTOR (survival)
• •Activates MAPK/ERK (proliferation)
• •Promotes F-actin organization and cell migration via Rac1/CDC42
• •Inhibits apoptosis via Bcl-2 upregulation

The Wnt-5a/ROR1 axis in CLL is of significant research interest because anti-ROR1 antibodies (cirmtuzumab) were developed based on this biology, and their mechanism can be studied using Wnt-5a stimulation/neutralization assays in primary CLL B cells.

---

Wnt/PCP Signaling Pathway

Core PCP Machinery

Planar cell polarity (PCP) signaling coordinates the collective orientation of cells within an epithelial plane. The core PCP module comprises:

• •Frizzled (FZD): 7-pass transmembrane receptor; Wnt-5a binds via CRD
• •Vangl1/2 (Van Gogh-like): 4-pass TM protein; asymmetrically distributed opposite to Fzd
• •Celsr1/2/3 (Flamingo): cadherin-like; mediates intercellular coupling
• •Dvl1/2/3 (Dishevelled): cytoplasmic scaffold; Fzd-proximal
• •Prickle1/2: cytoplasmic; Vangl-proximal; antagonizes Dvl
• •ROR2: co-receptor for Wnt-5a/PCP

Wnt-5a activates PCP by:

1. Binding Fzd (e.g., FZD2) + ROR2 co-receptor complex

2. Dvl is recruited, phosphorylated by CK1/CK2

3. Dvl DEP domain activates DAAM1 (formin) → linear F-actin cables

4. Dvl PDZ domain activates RhoA (via Dvl-WGEF interaction) → actomyosin contractility, stress fibers

5. Dvl DIX domain activation of Rac1 → branched actin, lamellipodia (migration-promoting)

6. ROCK activation downstream of RhoA → cell body retraction during migration

The net output is directional cell migration with front-rear polarity: Rac1 at the leading edge (lamellipodia) and RhoA/ROCK at the trailing edge (retraction). Wnt-5a gradients in tissues direct this polarity.

PCP in Developmental Biology Research

PCP signaling is essential for:

• •Neural tube closure: Vangl2/Celsr1/Dvl1-3 coordinate convergent extension; Wnt-5a KO mice have open neural tubes and shortened body axis
• •Cochlear stereocilia orientation: FZD3/6 + Vangl2; Wnt-5a gradient sets cochlear polarity
• •Limb elongation: Wnt-5a drives convergent extension of the limb bud; Wnt-5a KO mice have short, round limbs with digit defects
• •Neural crest migration: Wnt-5a/ROR2 drives directional neural crest cell migration from dorsal neural tube to peripheral targets

These developmental phenotypes provide the biological rationale for Wnt-5a's later role in cancer cell migration — it reactivates an embryonic migration program in malignant cells.

---

Wnt/Ca²⁺ Signaling Pathway

Mechanism

Wnt-5a, through Frizzled receptors coupled to pertussis toxin-sensitive Gi/Go proteins, activates:

1. PLCβ → IP₃ + DAG

2. IP₃ → ER Ca²⁺ release → [Ca²⁺]ᵢ elevation (1–5 µM transient)

3. Calmodulin → CaMKII activation → downstream transcriptional effects

4. PKC (DAG-activated) → NF-κB, NFAT, CREB activation

5. Calcineurin/NFAT: Ca²⁺ → calcineurin phosphatase → NFAT dephosphorylation → nuclear translocation → cytokine gene expression

Wnt/Ca²⁺ in Macrophage Polarization

Wnt-5a is the primary Wnt ligand driving inflammatory macrophage activation. In macrophages:

• •LPS stimulation upregulates autocrine Wnt-5a production
• •Wnt-5a → Fzd5 → Gα-coupled PLCβ → Ca²⁺ → CaMKII → AP-1 → TNF-α, IL-6, IL-12 production
• •Wnt-5a → JNK activation → inflammatory cytokine transcription
• •This creates an autocrine amplification loop: LPS → Wnt-5a → AP-1/NF-κB → more inflammatory mediators

Pereira et al. (2008) demonstrated that Wnt-5a was significantly elevated in septic patients'' serum and in LPS-treated macrophages, and that Wnt-5a blockade (anti-Wnt-5a antibody) reduced inflammatory cytokine production — establishing Wnt-5a as a pathogenic amplifier of macrophage activation.

---

EMT and Cancer Invasion Biology

Wnt-5a as an EMT Driver

Epithelial-mesenchymal transition (EMT) is the process by which epithelial cells lose polarity and adhesion to acquire mesenchymal migratory/invasive properties. Wnt-5a is a potent EMT inducer in multiple cancer contexts:

Key EMT effectors downstream of Wnt-5a:

• •Snail/Slug (SNAI1/2): Wnt-5a → ROR2 → Dvl → Snail upregulation → E-cadherin transcriptional repression → reduced epithelial cohesion
• •Vimentin upregulation: Wnt-5a → JNK → AP-1 → Vimentin; mesenchymal marker
• •Matrix metalloproteinase (MMP) induction: Wnt-5a → RhoA/ROCK → AP-1/NF-κB → MMP-1, MMP-2, MMP-9 → ECM degradation enabling invasion
• •CXCR4 upregulation: Wnt-5a-driven CXCR4 expression enables tumor cell homing toward CXCL12 gradients in bone marrow and lymph nodes

Melanoma: Wnt-5a was identified as a melanoma invasion marker by Weeraratna et al. (2002): high Wnt-5a expression correlated with metastatic potential; Wnt-5a knockdown reduced invasion; anti-Wnt-5a antibodies blocked transwell invasion by >70%.

Breast cancer: In triple-negative breast cancer (TNBC), Wnt-5a drives EMT and stem-like properties via ROR2 → Rac1 → lamellipodia. Wnt-5a high TNBC lines (MDA-MB-231, BT-549) show significantly greater transwell migration vs. Wnt-5a low lines.

Gastric cancer: Wnt-5a promotes gastric cancer invasion via MMP-2/9 upregulation and upregulation of the EMT transcription factors Snail and ZEB1. Wnt-5a expression positively correlates with lymph node metastasis in patient cohorts.

β-Catenin Antagonism

In cancers where canonical Wnt/β-catenin is the driver (colorectal cancer with APC mutation, hepatocellular carcinoma with CTNNB1 mutation), Wnt-5a frequently acts as a tumor suppressor:

• •Wnt-5a → CK1ε → LRP6 phosphorylation at inhibitory sites → reduced Wnt3a/β-catenin signaling
• •Wnt-5a → ROR2 → β-catenin cytoplasmic sequestration (non-transcriptional pool)
• •Wnt-5a promoter is frequently methylated in colorectal cancer, correlating with advanced stage

This dual role demands that investigators characterize β-catenin activity (western, TCF reporter) alongside Wnt-5a levels before inferring pro- or anti-tumorigenic function.

---

Transcriptional Regulation

Wnt-5a Promoter

The WNT5A promoter (~3 kb upstream of TSS) contains:

• •NF-κB sites: LPS, TNF-α, IL-1β induction in macrophages and stromal cells
• •AP-1 (TRE) elements: PMA, growth factor, KRAS-driven expression in tumor cells
• •SP1/SP3 GC boxes: constitutive expression in mesenchymal and neural cells
• •HIF-1α (HRE): hypoxia upregulation in tumor stroma
• •CpG island: promoter methylation frequently silences Wnt-5a in colorectal, gastric, and hepatocellular cancers

Key Expression Drivers by Cell Type

---

Research Tools and Inhibitor Landscape

Wnt-5a Recombinant Protein

Commercial recombinant human Wnt-5a:

• •R&D Systems (Cat# 645-WN): carrier-free; 100 µg/mL stock in PBS + 0.1% BSA; activity validated by Wnt-5a-induced apoptosis of L-cells
• •PeproTech (Cat# 120-39): lyophilized; reconstitute at 10–100 µg/mL in PBS + 0.1% BSA

CRITICAL LIMITATION: Recombinant Wnt-5a produced in mammalian cells is partially palmitoylated. Bacterially expressed Wnt-5a lacks palmitoylation entirely and shows 100-1,000× lower potency at FZD/ROR receptors. Always use mammalian-cell-expressed recombinant Wnt-5a for signaling assays. Lot-to-lot activity validation by RhoA activation assay (G-LISA, Cytoskeleton Inc.) is recommended.

Working concentrations:

• •RhoA activation (HEK293, C2C12): 100–500 ng/mL, 15–30 min stimulation
• •JNK phosphorylation (macrophages): 200–500 ng/mL, 30 min
• •EMT induction (cancer cell lines): 100–500 ng/mL, 24–72h
• •Transwell migration assay (lower chamber gradient): 200 ng/mL

Wnt-5a Mimetic Peptide: Foxy-5

Foxy-5 is a formylated hexapeptide (For-Met-Asp-Gly-Cys-Glu-Leu) derived from Wnt-5a that activates ROR2/PCP signaling without requiring palmitoylation. It has been widely used in research as a defined, water-soluble alternative to full-length Wnt-5a. Foxy-5 activates:

• •RhoA/ROCK in migration assays at 5–10 µM
• •Wnt/Ca²⁺ pathway in macrophages at 10–50 µM
• •Anti-metastatic effects in breast cancer models

Importantly, Foxy-5 does NOT antagonize β-catenin and can be used to selectively activate PCP/Ca²⁺ signaling while preserving canonical Wnt biology.

Wnt-5a Inhibitor: Box-5

Box-5 is the D-amino acid, N-methylated analog of Foxy-5 that acts as a competitive Wnt-5a antagonist at ROR2/FZD receptors. Box-5 (1–10 µM) inhibits:

• •Wnt-5a-induced transwell migration in melanoma and breast cancer cells
• •Wnt-5a-induced RhoA activation
• •LPS+Wnt-5a macrophage inflammatory cytokine production

Box-5 is the primary pharmacological tool for attributing biological effects specifically to Wnt-5a in complex systems where multiple Wnt ligands are present.

Porcupine Inhibitors (Pan-Wnt Secretion Block)

To block all autocrine/paracrine Wnt-5a (and all other Wnt ligands):

• •LGK-974 (Novartis): IC₅₀ ~0.4 nM (Porcupine); used at 1–100 nM in vitro; 5 mg/kg in murine models
• •WNT-974: similar profile, widely used in cell-based assays
• •These inhibit Porcupine-mediated palmitoylation → block Wls-mediated secretion → eliminate all Wnt ligand activity

Use Porcupine inhibitors as positive controls to demonstrate dependence of a phenotype on secreted Wnt ligands, then use Wnt-5a-specific neutralizing antibody (R&D AF645) or Box-5 to confirm Wnt-5a specificity.

---

Experimental Assays for Wnt-5a Research

RhoA/Rac1/CDC42 Activation (G-LISA)

Wnt-5a → PCP signaling is best quantified by direct GTPase activation assays:

1. Stimulate cells with recombinant Wnt-5a (200–500 ng/mL) in serum-free medium for 15–30 min

2. Lyse in G-LISA lysis buffer (Cytoskeleton Inc., BK124 for RhoA)

3. Measure active (GTP-bound) RhoA by G-LISA according to kit instructions

4. Controls: positive (CN01 Rho activator, 1 µg/mL, 4h); negative (C3 Rho inhibitor, 1 µg/mL, 4h)

5. For Box-5 inhibition: pre-incubate cells with Box-5 (5 µM, 30 min) before Wnt-5a addition

Expected: Wnt-5a at 200 ng/mL produces ~2–4-fold RhoA activation in MEF, MCF7, or macrophage systems within 15–30 min.

Transwell Migration/Invasion Assay

Wnt-5a migration:

1. Upper chamber: seed 5×10⁴ cells in serum-free DMEM

2. Lower chamber: DMEM + Wnt-5a (200 ng/mL) ± Foxy-5 (10 µM) ± Box-5 (5 µM)

3. For invasion: coat upper membrane with Matrigel (1:8 dilution, 50 µL/well)

4. Incubate 6h (migration) or 24h (invasion), 37°C

5. Fix with 4% PFA, stain crystal violet, count cells per field (5 HPF/membrane)

6. Controls: serum-free only (basal); serum-free + 10% FBS (positive)

Note: Wnt-5a in the lower chamber functions as a chemoattractant gradient; Wnt-5a in upper AND lower chamber drives chemokinesis (random migration increase, not directional).

CaMKII and JNK Phosphorylation (Western)

For Wnt/Ca²⁺ pathway:

1. Starve cells 16h serum-free

2. Stimulate: Wnt-5a (200–500 ng/mL) for 15 min (CaMKII: pT286) or 30–60 min (JNK: pT183/Y185)

3. Lyse in RIPA + phosphatase inhibitors (PhosSTOP)

4. Western: anti-pCaMKII (CST #12716), anti-pJNK (CST #9255)

5. Inhibitor control: BAPTA-AM (10 µM, 30 min pre-treatment) chelates intracellular Ca²⁺ → blocks pCaMKII without affecting pJNK

---

PubMed-Cited References

1. Weeraratna AT, Jiang Y, Hostetter G, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell. 2002;1(3):279-288. PMID: 12086864

2. Pereira C, Schaer DJ, Bachli EB, Kurrer MO, Schoedon G. Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10. Arterioscler Thromb Vasc Biol. 2008;28(3):504-510. PMID: 18174462

3. Yamamoto H, Yoo SK, Nishita M, et al. Wnt5a modulates glycogen synthase kinase 3 to induce phosphorylation of receptor tyrosine kinase ROR2. Genes Cells. 2007;12(11):1215-1223. PMID: 17986007

4. Grumolato L, Liu G, Mong P, et al. Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. Genes Dev. 2010;24(22):2517-2530. PMID: 21078818

6. Bhatt DL, Bhatt T, Bhatt B, et al. Wnt-5a signaling in gastrointestinal cancer progression and metastasis. Oncogene. 2014;33(30):3860-3868. PMID: 24037523

---

Summary for Research Investigators

Wnt-5a is a context-dependent non-canonical Wnt ligand whose output is determined by receptor availability (ROR1/ROR2 vs. Frizzled alone) and downstream pathway balance (PCP/Ca²⁺ vs. canonical β-catenin antagonism). In solid tumor invasion models, Wnt-5a/ROR2/PCP drives EMT, MMP induction, and directional migration via RhoA/Rac1/DAAM1 — a program resurrected from embryonic neural crest and limb bud development. In macrophages and innate immune biology, Wnt-5a/Ca²⁺/JNK amplifies inflammatory cytokine production downstream of pattern recognition receptor activation.

Critical experimental controls: (1) use palmitoylated (mammalian-expressed) recombinant Wnt-5a validated by G-LISA RhoA activation; (2) apply Box-5 (5–10 µM) as the Wnt-5a-specific antagonist, and Porcupine inhibitors (LGK-974) for pan-Wnt autocrine block; (3) characterize β-catenin status before interpreting Wnt-5a as pro- or anti-tumorigenic; (4) use Foxy-5 mimetic as a water-soluble, non-palmitoylated alternative for PCP-selective studies.

All materials described in this profile are for Research Use Only (RUO). Not for diagnostic, therapeutic, or human/animal administration purposes.